Evogene Ltd. (EVGN)

0,6251 -0,0323 (-4,91%) Börsenschluss: 04:00PM EDT

Evogene Ltd.

13 Gad Feinstein Street
Park Rehovot PO Box 4173
Rehovot 7414002
Israel
972 8 931 1900
https://www.evogene.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 142

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Ofer Haviv CPA	CEO & President	390k	N/A	1966
Dr. Nir Arbel	Chief Product Officer	228k	N/A	1980
Dr. Brian Ember	Chief Executive Officer of AgPlenus Ltd	287k	N/A	1976
Dr. Elran Hillel Haber M.B.A., Ph.D.	Chief Executive Officer of Biomica Ltd	302k	N/A	1980
Mr. Amit Noam Capt. res.	Chief Executive Officer of Lavie Bio Ltd.	136k	N/A	1982
Mr. Yaron Eldad	Chief Financial Officer	N/A	N/A	1965
Mr. Mark Kapel	Chief Technology Officer	276k	N/A	1977
Rachel Pomerantz Gerber	Head of Investor Relations	N/A	N/A	N/A
Mr. Sassi Masliah	Vice President of Corporate Development	245k	N/A	1979
Ms. Liat Foigel Wejgman	Vice President of Human Resources	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Corporate Governance

Evogene Ltd.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.